Drug intelligence / Profile preview

NQ2020

Development stage: Preclinical
Lead developer: Novaliq
Modality: Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

NQ2020 is a preclinical-stage protein therapeutic being developed by Novaliq for the treatment of diabetic retinopathy. The drug is formulated using Novaliq's proprietary EyeSol® technology, which is a water-free, perfluorohexyloctane-based platform designed to enable the topical delivery of biologics to the posterior segment of the eye. NQ2020 functions as an anti-angiogenic agent, aiming to inhibit the pathological neovascularization associated with diabetic retinopathy. By utilizing the EyeSol® platform, NQ2020 is intended for topical ocular administration (eye drops), potentially offering a non-invasive alternative to traditional intravitreal injections for retinal diseases.

Beyond the preview

Go deeper on NQ2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NQ2020.

Explore the full profile